Earnings ·
Cellectis S.A. filed its interim report for the six months ended June 30, 2026, revealing a net loss of $39.58 million…
CLLSCellectis S.A.
Cellectis S.A. filed its interim report for the six months ended June 30, 2026, revealing a net loss of $39.58 million compared to $41.86 million in the prior year period. Revenues declined significantly from $27.38 million to $11.01 million, while research and development expenses increased to $52.17 million from $45.01 million. The company reported a net financial gain of $9.18 million, driven by reduced financial expenses of $7.39 million against $29.68 million in the previous year. Cash and cash equivalents decreased to $35.59 million from $61.53 million at year-end 2025. Cellectis S.A. operates in the biotechnology industry, focusing on developing allogeneic cellular immunotherapies for cancer treatment.